• Synergistic CDK4/6 and BET Inhibition in Pancreatic Cancer

  2026-06-04

  Gu et al. demonstrate that co-inhibition of CDK4/6 and BET proteins in pancreatic ductal adenocarcinoma (PDAC) synergistically suppresses tumor growth and epithelial-to-mesenchymal transition (EMT) via modulation of the GSK3β-Wnt/β-catenin pathway. These mechanistic insights present a promising combinatorial strategy for overcoming resistance and improving outcomes in pancreatic cancer models.

• Ciprofloxacin in Advanced Antimicrobial Resistance Modeling

  2026-06-04

  Explore how Ciprofloxacin, a potent fluoroquinolone antibiotic, enables next-generation antimicrobial resistance research. This article uncovers advanced assay design, protocol parameters, and practical insights not found in standard workflows.

• Streptavidin-FITC: Precision Biotin Detection for Advanced A

  2026-06-03

  Streptavidin-FITC empowers researchers with ultra-sensitive, quantitative detection of biotinylated molecules across imaging and cytometry workflows. Explore evidence-driven protocol enhancements, troubleshooting strategies, and innovations from recent lipid nanoparticle trafficking studies that unlock new assay capabilities.

• Ciprofloxacin: Mechanism, Evidence, and Research Integration

  2026-06-03

  Ciprofloxacin is a well-characterized fluoroquinolone antibiotic that acts as a DNA gyrase inhibitor, crucial for antimicrobial resistance research. Its potent, defined mechanism and high-purity availability from APExBIO make it a benchmark compound for laboratory investigations into bacterial DNA replication inhibition.

• Redox-Responsive Peptide Coacervates Advance mRNA Delivery

  2026-06-02

  This study introduces a minimalist, redox-responsive peptide coacervate (HBpep-SS4) that achieves high-efficiency mRNA encapsulation and cytosolic release, outperforming previous peptide-based systems in stability and control. The findings have broad implications for developing safer, more effective platforms for mRNA delivery and intracellular gene regulation.

• Maraviroc (UK-427857): Applied Workflows for CCR5 Antagonism

  2026-06-02

  Maraviroc (UK-427857) enables high-fidelity inhibition of CCR5, unlocking advanced assays for HIV-1 entry, neuroinflammation, and novel RA models. This guide translates recent breakthroughs into actionable workflows and troubleshooting insights, making APExBIO’s Maraviroc a cornerstone for translational immunology.

• Carvacrol (5-Isopropyl-2-Methylphenol): Mechanisms and Resea

  2026-06-01

  Carvacrol, a monoterpene phenol, exhibits potent antibacterial, antioxidant, and anticancer activities. Its efficacy in cell cycle and apoptosis research is supported by downregulation of Notch-1/Jagged-1 and induction of G0/G1 arrest. APExBIO's Carvacrol is a benchmark reagent for redox and TRP channel studies.

• Danazol in Bench Research: Protocols, Models, and Optimizati

  2026-06-01

  Danazol (Danocrine) is a cornerstone for modeling steroidogenesis and endocrine modulation in translational research. Here, we dissect practical workflows, highlight cutting-edge applications, and offer troubleshooting strategies based on the latest evidence and high-purity APExBIO supply.

• STING agonist-1: Advanced Strategies for B Cell-Driven Immun

  2026-05-31

  Explore the unique mechanistic insights and advanced applications of STING agonist-1 in B cell activation and tertiary lymphoid structure research. This article bridges cutting-edge evidence with practical assay design, offering a distinct perspective for cancer immunology researchers.

• Dibutyryl-cAMP, Sodium Salt: Decoding Synaptic Resilience in

  2026-05-30

  Explore how Dibutyryl-cAMP, sodium salt empowers neuroscience research by enabling direct manipulation of cAMP signaling in live human brain slice cultures. This article uniquely bridges bench applications with insights from advanced biomarker studies, offering protocols and translational context for cAMP pathway investigations.

• Paeoniflorigenone Targets HIF1A to Inhibit Cholangiocarcinom

  2026-05-29

  This study demonstrates that paeoniflorigenone (PFG), a natural compound from Moutan cortex, suppresses cholangiocarcinoma (CCA) progression by targeting HIF1A and enhances cisplatin chemotherapy efficacy. The findings suggest a promising multi-target approach for overcoming drug resistance and improving therapeutic outcomes in CCA.

• Solving Cell Death Assay Challenges with Cathepsin B Inhibit

  2026-05-29

  This article provides a scenario-driven, evidence-based guide for deploying Cathepsin B inhibitor CA-074 (SKU A1926) in cell viability, necroptosis, and metastasis assays. By integrating recent mechanistic advances and validated best practices, it demonstrates how SKU A1926 offers reproducibility, selectivity, and workflow compatibility for biomedical researchers. Explore how CA-074 elevates assay reliability and data interpretation for advanced cell death research.

• Necrostatin-1: Bridging Necroptosis Research to Inflammatory

  2026-05-28

  Explore how Necrostatin-1, a potent RIP1 kinase inhibitor, uniquely advances necroptosis research and translational models for inflammatory disease. This article delivers deeper mechanistic context and assay protocol guidance for researchers.

• EdU Imaging Kits (Cy3): Advanced Cell Cycle S-Phase Analysis

  2026-05-28

  Discover how EdU Imaging Kits (Cy3) enable precise, antibody-free detection of S-phase DNA synthesis. This article explores advanced mechanisms, practical innovations, and new assay decision-making insights for researchers seeking next-level cell proliferation analysis.

• Ciprofloxacin Workflows: Optimizing Fluoroquinolone Research

  2026-05-27

  Ciprofloxacin, a fluoroquinolone antibiotic, is pivotal for dissecting bacterial DNA replication inhibition and modeling antimicrobial resistance in complex systems. Recent advances fuse Ciprofloxacin’s mechanism with nanotheranostic delivery, opening new frontiers in targeted research and synergistic therapy. Unlock robust protocols, real-world troubleshooting, and actionable insights from both resistance models and innovative cancer research.

16035 records 1/1069 page Next 12345 下5页 Last page